This CPG Company Achieves Substantial Fiscal 2023 Revenue & EBITDA Growth
This CPG Company Achieves Substantial Fiscal 2023 Revenue & EBITDA Growth
Delivra Health Brands Inc. (TSXV:DHB) (OTCQB:DHBUF), a prominent player in the health and wellness consumer packaged goods (CPG) sector, recently disclosed its financial and operational results for the fiscal year ending June 30, 2023.
Delivra Health Brands 多倫多證券交易所股票代碼：DHB）（OTCQB：DHB）（場外交易代碼：DHBUF）是健康和保健消費品（CPG）領域的傑出參與者，最近披露了截至2023年6月30日的財年的財務和運營業績。
The company, known for its innovative brands Dream Water and LivRelief, focuses on delivering high-quality products to the global market.
該公司以其創新品牌Dream Water和LivRelief而聞名，專注於向全球市場提供高質量的產品。
See Also: EXCLUSIVE: Cannabis Companies On Importance Of Brands Going Mainstream, Entry Into Consumer Packaged Good Market
另請參閱： 獨家：大麻公司談品牌走向主流、進入消費者包裝商品市場的重要性
Financial Highlights
財務要聞
- Net revenue increased by 20% to $9,791 compared to $8,139 in fiscal 2022, primarily due to higher sales in the USA.
- Gross profit reached $4,823 with a 49% gross profit margin, compared to $2,604 and a 32% margin in fiscal 2022, driven by reduced fees, lower indirect cost of sales and fewer financial inventory write-downs.
- Total expenses, including SG&A and excluding non-cash items, decreased by 23% to $4,704 compared to $6,145 in fiscal 2022, resulting from operational changes and cost reductions.
- Adjusted EBITDA improved by 119% to $517 in fiscal 2023, up from $2,765 in fiscal 2022, attributed to higher net sales, a stronger gross margin, and overall expense reduction.
- 淨收入增長了20％，達到9,791美元，而2022財年的收入爲8,139美元，這主要是由於在美國的銷售額增加。
- 毛利達到4,823美元，毛利率爲49％，而2022財年的毛利率爲2,604美元，利潤率爲32％，這得益於費用降低、間接銷售成本降低和財務庫存減記減少。
- 由於運營變化和成本降低，總支出（包括銷售和收購以及不包括非現金項目）與2022財年的6,145美元相比下降了23％，至4,704美元。
- 調整後的息稅折舊攤銷前利潤從2022財年的2765美元增長了119％，至2023財年的517美元，這要歸因於淨銷售額的增加、毛利率的提高以及總體開支的減少。
Gord Davey, president and CEO of Delivra Health, expressed satisfaction with the company's achievements and outlined future growth plans. "In the coming year, we expect to continue to increase our revenues and profitability through a combined focus on Canada, USA, international and e-commerce markets," he said.
Gord DaveyDelivra Health總裁兼首席執行官對公司取得的成就表示滿意，並概述了未來的增長計劃。他說：“在來年，我們預計將通過共同關注加拿大、美國、國際和電子商務市場，繼續增加收入和盈利能力。”
In May, the company announced that its wholly owned subsidiary, Delivra Inc., granted a subsidiary of Canopy Growth Corporation (NASDAQ:CGC) a strategic licensing agreement to manufacture, distribute, and sell LivRelief brand-infused topical products in Canada.
5月，該公司宣佈其全資子公司Delivra Inc. 授予了一家子公司 Canopy GROWT 納斯達克股票代碼：CGC）一項戰略許可協議，旨在在加拿大製造、分銷和銷售注入LivRelief品牌的外用產品。
Price Action
價格走勢
DHBUF shares were trading down at 38.27% at $0.01 per share Wednesday afternoon.
週三下午，DHBUF股價下跌38.27％，至每股0.01美元。
Related News
相關新聞
Delivra Health Stock Soars On Q3 FY23 Positive Adjusted EBITDA, Here Are The Details
Delivra Health 股票在 23 財年第三季度調整後息稅折舊攤銷前利潤爲正值後飆升，詳情如下
Delivra Health Stock Trading Higher On Reached Profitability
Delivra Health 股票在實現盈利後交易走高
Delivra Health Brands Sells Its Lucky Lake Facility For $3M
Delivra Health Brands 以 300 萬美元的價格出售其幸運湖設施
Image by El Planteo
圖片由 El Planteo